Correction: GRK3 deficiency elicits brain immune activation and psychosis.

Autor: Sellgren CM; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden.; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm & Stockholm Health Care Services, Region Stockholm, Sweden., Imbeault S; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Larsson MK; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Oliveros A; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA., Nilsson IAK; Translational Psychiatry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Codeluppi S; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Orhan F; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Bhat M; Research and Development, Innovative Medicines, Personalised Healthcare and Biomarkers, Translational Science Centre, Science for Life Laboratory, AstraZeneca, Solna, Sweden.; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Tufvesson-Alm M; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Gracias J; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Kegel ME; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Zheng Y; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Faka A; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Svedberg M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Powell SB; Department of Psychiatry, University of California San Diego, La Jolla, CA, USA., Caldwell S; Department of Psychiatry, University of California San Diego, La Jolla, CA, USA., Kamenski ME; Department of Psychiatry, University of California San Diego, La Jolla, CA, USA., Vawter MP; Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine School of Medicine, Irvine, CA, USA., Schulmann A; Functional Genomics Laboratory, Department of Psychiatry and Human Behavior, University of California Irvine School of Medicine, Irvine, CA, USA.; Human Genetics Branch, National Institute of Mental Health, Bethesda, MD, USA., Goiny M; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Svensson CI; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Hökfelt T; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden., Schalling M; Translational Psychiatry, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Schwieler L; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Cervenka S; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm & Stockholm Health Care Services, Region Stockholm, Sweden., Choi DS; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.; Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA., Landén M; Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Engberg G; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden. goran.engberg@ki.se., Erhardt S; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Molecular psychiatry [Mol Psychiatry] 2022 Mar; Vol. 27 (3), pp. 1855.

Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity.

Autor: Kegel ME; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Johansson V; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: viktoria.johansson@ki.se., Wetterberg L; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Bhat M; Protein Biomarkers, Personalized Healthcare & Biomarker Laboratories, Innovative Medicines, Gothenburg, Sweden., Schwieler L; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Cannon TD; Departments of Psychology and Psychiatry, Yale University, New Haven, USA., Schuppe-Koistinen I; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; AstraZeneca, Research & Development, Innovative Medicines, Personalized Healthcare & Biomarkers, Translational Science Centre, Science for Life Laboratory, Solna, Sweden., Engberg G; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Landén M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden., Hultman CM; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Erhardt S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Psychiatry research [Psychiatry Res] 2017 Jan; Vol. 247, pp. 105-112. Date of Electronic Publication: 2016 Nov 16.

Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.

Autor: Schwieler L; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Larsson MK; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Skogh E; Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden., Kegel ME; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Orhan F; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Abdelmoaty S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Finn A; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Bhat M; AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Samuelsson M; Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden., Lundberg K; Department of Clinical and Experimental Medicine, Section of Psychiatry, Faculty of Health Sciences, Linköping University, Linköping, Sweden., Dahl ML; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden., Sellgren C; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Schuppe-Koistinen I; AstraZeneca, Research & Development, Innovative Medicines, Personalised Healthcare & Biomarkers, Science for Life Laboratory, Solna, Sweden, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Svensson C; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Erhardt S; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden., Engberg G; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Publikováno v: Journal of psychiatry & neuroscience : JPN [J Psychiatry Neurosci] 2015 Mar; Vol. 40 (2), pp. 126-33.